Funding Boom Time Continues For UK Life Sciences
Accounted For 60% Of Biotech Venture Capital Invested In Europe
Executive Summary
Nearly £1.6bn was invested in the pharma, biotech and life sciences sector in the UK from March to May, which means £2.39bn has been raised in the year to date, more than in the whole of 2020.
You may also be interested in...
Eli Lilly To Explore MiNA's Small Activating RNA Technology
Advances in small activating RNAs, pioneered by MiNA Therapeutics, have caught the eye of Eli Lilly, and could be the next platform to exploit gene control mechanisms to produce a new therapeutic modality.
NeRRe: Advancing Neurokinin Receptor Antagonists
Starting the year with a cash injection of £23m, 2012 GSK spin-out NeRRe Therapeutics intends to advance its neurokinin receptor antagonist pipeline towards late-stage clinical development. CEO Mary Kerr spoke to Scrip's Mike Ward at the 2017 Biotech Showcase in San Francisco.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.